Karmele Valencia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3775831/publications.pdf

Version: 2024-02-01

567281 713466 24 914 15 21 citations h-index g-index papers 25 25 25 1689 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer Letters, 2022, 529, 70-84.	7.2	51
2	Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	5
3	Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer. Cancer Discovery, 2022, 12, 1356-1377.	9.4	22
4	Molecular biomarkers in early stage lung cancer. Translational Lung Cancer Research, 2021, 10, 1165-1185.	2.8	23
5	Exosomes in Liquid Biopsy: The Nanometric World in the Pursuit of Precision Oncology. Cancers, 2021, 13, 2147.	3.7	35
6	Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies. Cancers, 2021, 13, 3016.	3.7	38
7	Abstract PO-089: Identification of a LAMC2-regulated network featuring targetable effectors for dual therapies in pancreatic cancer., 2021,,.		0
8	Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. Nature Cancer, 2020, 1, 75-85.	13.2	68
9	Liver Kinase B1 (LKB1) Loss Has its p-ERKs: ERK Inactivation as a Vulnerability in NSCLC With LKB1 Mutations. Journal of Thoracic Oncology, 2020, 15, 311-313.	1.1	0
10	The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas. Journal of Clinical Investigation, 2020, 130, 1879-1895.	8.2	29
11	Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1. Scientific Reports, 2019, 9, 15400.	3.3	13
12	An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nature Communications, 2017, 8, 14294.	12.8	119
13	All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS. Molecular and Cellular Oncology, 2017, 4, e1314239.	0.7	10
14	The Usefulness of Bone Biomarkers for Monitoring Treatment Disease: A Comparative Study in Osteolytic and Osteosclerotic Bone Metastasis Models. Translational Oncology, 2017, 10, 255-261.	3.7	10
15	Matrix-Gla protein promotes osteosarcoma lung metastasis and associates with poor prognosis. Journal of Pathology, 2016, 239, 438-449.	4.5	42
16	Microvesicles: Isolation, Characterization for In Vitro and In Vivo Procedures. Methods in Molecular Biology, 2016, 1372, 181-192.	0.9	4
17	A gene signature of bone metastatic colonization sensitizes for tumor-induced osteolysis and predicts survival in lung cancer. Oncogene, 2014, 33, 5090-5099.	5.9	35
18	miRNA cargo within exosomeâ€ike vesicle transfer influences metastatic bone colonization. Molecular Oncology, 2014, 8, 689-703.	4.6	155

#	Article	IF	CITATION
19	RHOB influences lung adenocarcinoma metastasis and resistance in a hostâ€sensitive manner. Molecular Oncology, 2014, 8, 196-206.	4.6	27
20	miR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis. Bone, 2013, 52, 532-539.	2.9	45
21	Inhibition of Collagen Receptor Discoidin Domain Receptor-1 (DDR1) Reduces Cell Survival, Homing, and Colonization in Lung Cancer Bone Metastasis. Clinical Cancer Research, 2012, 18, 969-980.	7.0	121
22	Receptor of Activated Protein C Promotes Metastasis and Correlates with Clinical Outcome in Lung Adenocarcinoma. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 96-105.	5.6	45
23	Inhibition of discoidin domain receptor-1 (DDR1) impairs tumor-induced osteoclastogenesis preventing bone metastatic homing and colonization. Bone, 2011, 48, S48-S49.	2.9	0
24	Tumor–stromal interactions of the bone microenvironment: in vitro findings and potential in vivo relevance in metastatic lung cancer models. Clinical and Experimental Metastasis, 2011, 28, 779-791.	3.3	17